ADME-Predictive Evolutionary Chemistry Methods

Information

  • Research Project
  • 6550097
  • ApplicationId
    6550097
  • Core Project Number
    R43AI052576
  • Full Project Number
    1R43AI052576-01
  • Serial Number
    52576
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/2002 - 22 years ago
  • Project End Date
    12/31/2002 - 21 years ago
  • Program Officer Name
    LITTERST, CHARLES L.
  • Budget Start Date
    7/1/2002 - 22 years ago
  • Budget End Date
    12/31/2002 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/21/2002 - 22 years ago
Organizations

ADME-Predictive Evolutionary Chemistry Methods

DESCRIPTION (provided by applicant): Evolutionary Chemistry (EC) is a drug discovery methodology developed to efficiently identify lead pharmaceutical compounds from enormous but focused small molecule libraries. The methodology involves biocatalyzed small molecule library assembly, lead compound selection through the application of evolutionary pressures, and amplification of selected compounds. The frequency at which EC-derived drug leads become drugs would be significantly increased if the lead compound selection components of this methodology demanded not only high affinity for the drug target, but also other drug-like properties. For lead compounds that survive functional screens to become drug candidates, favorable absorption, distribution, metabolism, elimination (ADME), and toxicity properties are all critical determinants of clinical success. The goal of the proposed research is to develop and validate ADME-predictive lead compound selection methods that can be integrated into the EC technology. The lead compound selection methods to be investigated would demand that EC-derived lead compounds have, in addition to high drug target affinity, favorable membrane permeability, serum protein affinity, and metabolism properties. The long-term objective of this research endeavor is to meet medical needs through the application of this improved technology to important drug targets.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    85000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:85000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    INVENUX, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    DENVER
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    80221
  • Organization District
    UNITED STATES